NASDAQ:REXN

Rexahn Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range N/A
50-Day Range
$1.81
$2.24
52-Week Range N/A
Volume2,579 shs
Average Volume162,968 shs
Market Capitalization$8.11 million
P/E RatioN/A
Dividend YieldN/A
Beta0.98

Receive REXN News and Ratings via Email

Sign-up to receive the latest news and ratings for Rexahn Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Rexahn Pharmaceuticals logo

About Rexahn Pharmaceuticals

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

0.48 out of 5 stars

Medical Sector

1702nd out of 2,100 stocks

Pharmaceutical Preparations Industry

728th out of 831 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Rexahn Pharmaceuticals (NASDAQ:REXN) Frequently Asked Questions

What stocks does MarketBeat like better than Rexahn Pharmaceuticals?

Wall Street analysts have given Rexahn Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rexahn Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Rexahn Pharmaceuticals' earnings last quarter?

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) posted its earnings results on Wednesday, August, 7th. The company reported ($0.61) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.95) by $0.34.
View Rexahn Pharmaceuticals' earnings history
.

When did Rexahn Pharmaceuticals' stock split? How did Rexahn Pharmaceuticals' stock split work?

Rexahn Pharmaceuticals's stock reverse split on the morning of Friday, April 12th 2019. The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 11th 2019. An investor that had 100 shares of Rexahn Pharmaceuticals stock prior to the reverse split would have 8 shares after the split.

Who are Rexahn Pharmaceuticals' key executives?

Rexahn Pharmaceuticals' management team includes the following people:
  • Mina Patel Sooch, President, Chief Executive Officer & Director
  • Bernhard Hoffmann, Vice President-Corporate Development & Operations
  • Amy Rabourn, Chief Accounting Officer & Vice President-Finance
  • Konstantinos Charizanis, Senior Director-Market Strategy, R&D
  • Drey Coleman, Director-Clinical Operations & Vendor Management

Who are some of Rexahn Pharmaceuticals' key competitors?

What other stocks do shareholders of Rexahn Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), CorMedix (CRMD), (SLS), Dynavax Technologies (DVAX), Novavax (NVAX), AcelRx Pharmaceuticals (ACRX), Celsion (CLSN), CytRx (CYTR) and SCYNEXIS (SCYX).

What is Rexahn Pharmaceuticals' stock symbol?

Rexahn Pharmaceuticals trades on the NASDAQ under the ticker symbol "REXN."

How much money does Rexahn Pharmaceuticals make?

Rexahn Pharmaceuticals has a market capitalization of $0.00.

How many employees does Rexahn Pharmaceuticals have?

Rexahn Pharmaceuticals employs 5 workers across the globe.

What is Rexahn Pharmaceuticals' official website?

The official website for Rexahn Pharmaceuticals is www.rexahn.com.

Where are Rexahn Pharmaceuticals' headquarters?

Rexahn Pharmaceuticals is headquartered at 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850.

How can I contact Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The company can be reached via phone at (248) 681-9815 or via email at [email protected]


This page was last updated on 6/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.